Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OTX-TIC

Other · developed by Ocular Therapeutix

Phase 2 Most advanced trial (none active)
OCUL Developer
1 Registered trials

What is OTX-TIC?

OTX-TIC is an intracameral implant injected into the anterior chamber of the eye, also named OTX-TIC high dose Travoprost Intracameral Implant. It is studied in open-angle glaucoma and ocular hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Ophthalmology
Developer
Ocular Therapeutix, Inc. (OCUL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05335122 Phase 2 Open Angle Glaucoma Completed OCUL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ocular HypertensionOpen Angle Glaucoma

More from Ocular Therapeutix

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the OCUL page.

Follow OCUL, the company behind OTX-TIC

See OCUL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OCUL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.